Predicting Biochemical Failure in Irradiated Patients With Prostate Cancer by Tumour Volume Measured by Multiparametric MRI.
MRI
Prostate cancer
radiation oncology
tumour volume
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
15
07
2020
revised:
29
07
2020
accepted:
05
08
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
We examined the prognostic value of intraprostatic gross tumour volume (GTV) as measured by multiparametric MRI (mpMRI) in patients with prostate cancer following (primary) external beam radiation therapy (EBRT). In a retrospective monocentric study, we analysed patients with prostate cancer (PCa) after EBRT. GTV was delineated in pre-treatment mpMRI (GTV-MRI) using T2-weighted images. Cox-regression analyses were performed considering biochemical failure recurrence-free survival (BRFS) as outcome variable. Among 131 patients, after a median follow-up of 57 months, biochemical failure occurred in 27 (21%). GTV-MRI was not correlated with % of positive biopsy cores, Gleason score and initial PSA (all r<0.2) and only moderately correlated with cT stage (r=0.32). In univariate analysis, cT stage, Gleason score and GTV-MRI were higher in subjects with shorter BRFS (p<0.05). GTV-MRI remained a significant predictor for BRFS in multivariate analyses, independent of Gleason score and cT stage. GTV, defined using mpMRI, provides incremental prognostic value for BRFS, independent of established risk factors. This supports the implementation of imaging-based GTV for risk-stratification, although further validation is needed.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We examined the prognostic value of intraprostatic gross tumour volume (GTV) as measured by multiparametric MRI (mpMRI) in patients with prostate cancer following (primary) external beam radiation therapy (EBRT).
PATIENTS AND METHODS
METHODS
In a retrospective monocentric study, we analysed patients with prostate cancer (PCa) after EBRT. GTV was delineated in pre-treatment mpMRI (GTV-MRI) using T2-weighted images. Cox-regression analyses were performed considering biochemical failure recurrence-free survival (BRFS) as outcome variable.
RESULTS
RESULTS
Among 131 patients, after a median follow-up of 57 months, biochemical failure occurred in 27 (21%). GTV-MRI was not correlated with % of positive biopsy cores, Gleason score and initial PSA (all r<0.2) and only moderately correlated with cT stage (r=0.32). In univariate analysis, cT stage, Gleason score and GTV-MRI were higher in subjects with shorter BRFS (p<0.05). GTV-MRI remained a significant predictor for BRFS in multivariate analyses, independent of Gleason score and cT stage.
CONCLUSION
CONCLUSIONS
GTV, defined using mpMRI, provides incremental prognostic value for BRFS, independent of established risk factors. This supports the implementation of imaging-based GTV for risk-stratification, although further validation is needed.
Identifiants
pubmed: 33144456
pii: 34/6/3473
doi: 10.21873/invivo.12187
pmc: PMC7811616
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3473-3481Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Magn Reson Imaging. 2017 Aug;46(2):483-489
pubmed: 28176411
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):62-9
pubmed: 17707266
J Urol. 2006 May;175(5):1605-12
pubmed: 16600713
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e787-93
pubmed: 22331003
Radiat Oncol. 2013 Jul 22;8:183
pubmed: 23875672
JAMA. 1999 Apr 21;281(15):1395-400
pubmed: 10217055
Brachytherapy. 2018 Mar - Apr;17(2):291-297
pubmed: 29137956
Cancer. 1990 Sep 15;66(6):1225-33
pubmed: 2400973
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):351-7
pubmed: 16530339
Theranostics. 2017 Jan 1;7(1):228-237
pubmed: 28042330
J Clin Oncol. 2004 Sep 15;22(18):3726-32
pubmed: 15365069
Radiat Oncol. 2018 Apr 12;13(1):65
pubmed: 29650029
Urol Oncol. 2020 Jun;38(6):600.e1-600.e8
pubmed: 31953005
Strahlenther Onkol. 2003 Aug;179(8):521-6
pubmed: 14509950
J Urol. 2003 Jun;169(6):2136-41
pubmed: 12771735
Urol Oncol. 2018 Oct;36(10):471.e11-471.e18
pubmed: 30122344
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
J Magn Reson Imaging. 2017 Mar;45(3):908-916
pubmed: 27442039
Radiother Oncol. 2015 May;115(2):186-90
pubmed: 25935742
Tomography. 2019 Sep;5(3):292-299
pubmed: 31572790
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):665-71
pubmed: 18760545
BJU Int. 2017 Nov;120(5B):E45-E51
pubmed: 27987524
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
World J Urol. 2016 Apr;34(4):525-32
pubmed: 26293117
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478
J Urol. 2000 Nov;164(5):1596-600
pubmed: 11025712
J Natl Compr Canc Netw. 2019 May 1;17(5.5):583-586
pubmed: 31117038
Radiology. 2008 Apr;247(1):141-6
pubmed: 18258811
Eur Radiol. 2015 Sep;25(9):2665-72
pubmed: 25820537
Urology. 2008 Apr;71(4):554-60
pubmed: 18308373
Ann Surg Oncol. 2013 Sep;20(9):3133-9
pubmed: 23720069
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1141-8
pubmed: 22099043
Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):247-51
pubmed: 8823282
Clin Cancer Res. 2014 Jul 15;20(14):3705-11
pubmed: 24850842
AJR Am J Roentgenol. 2010 Jun;194(6):W477-82
pubmed: 20489065
Eur Urol. 2016 Nov;70(5):829-836
pubmed: 26795686
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):707-11
pubmed: 22425220
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):743-50
pubmed: 20133067
Eur J Nucl Med Mol Imaging. 2016 May;43(5):889-897
pubmed: 26592938